



Exhibit 99.1

Second Quarter 2008 Webcast

July 24, 2008

Safe Harbor Statement

Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on July 24, 2008, and Alcon does not undertake any obligation to update any of the forward-looking statements or forward-looking information. Although Alcon believes that these statements are based on reasonable assumptions within the bounds of its knowledge of its businesses and operations, there are a number of factors that may cause actual results to differ from these statements. Factors that might cause these differences include, but are not limited to, the uncertainty of market acceptance of our products by the worldwide medical community; uncertainty of clinical trial results for expanded FDA approval submissions for our current products and initial approval of our products under development; product liability claims; the occurrence of excessive property and casualty, general liability or business interruption losses, for which we are self insured; manufacturing issues; and risks inherent in international transactions. For additional factors, which could cause actual results to differ from expectations, reference is made to the periodic reports filed by the company with the Securities and Exchange Commission under the Securities Exchange Act of 1934 as amended. Additional information about risk factors also can be found in the Company's Form 20-F filed with the SEC dated March 18, 2008, under the heading "Risk Factors". All these documents are available publicly and upon request from the Alcon Investor Relations Department at 817-551-8805 or www.alcon.com.


Business Overview

Cary Rayment

Chairman, President & CEO


Second Quarter Sales Highlights

2nd Qtr



Dollars in millions

June 2008 YTD




Dollars in millions

* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.

Q2 2008 Geographic Sales and Growth


Q2 2008 Sales by Geography




* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

Pharmaceutical Sales

Q2 2008 Sales by Product Line



2nd Qtr



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

(dollars in millions)

Gaining Market Share in Pharmaceuticals

<u>RX Growth</u>	Global March YTD		US May 2008	
	Brand	Market	Brand	Market
TRAVATAN® Family	23.4%	8.7%	12.7%	-0.3%
Azopt®	8.5%	5.5%	19.1%	5.7%
Vigamox® *	26.0%	8.0%	-1.0%	-3.4%
Tobradex®	0.7%	7.0%	-6.7%	-3.6%
Nevanac®	44.4%	2.3%	22.5%	10.9%
Patanol® + Pataday™	25.4%	1.9%	-1.8%	-8.3%
CiproDex® *	7.4%	1.7%	6.6%	0.8%


* Moxifloxacin, the active ingredient in **Vigamox®**, is licensed to Alcon from Bayer HealthCare AG.
CiproDex® is a registered trademark of Bayer AG and licensed to Alcon by Bayer HealthCare AG.

Source: Global-IMS US-WK Health

TRAVATAN® Global Market Success

Global Glaucoma Market Share by Product


The Travatan® family is #2 prostaglandin drug for Glaucoma based upon global market share data.



Source: IMS

Glaucoma growth in Japan


TRAVATANZ™ Share of Japanese Prostaglandin Market



Source: IMS


Patanol® Family Continues as Market Leader

U.S. Patanol® Family Market Share Growth



Source: WK Health


Japan Patanol® Unit Market Share Growth




Source: IMS

Surgical Sales

Q2 2008 Sales by Product Line




2nd Qtr



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

(dollars in millions)


Positive Phaco Machine Share Growth



Source: Q1 2008 Market Scope


Continued Alcon IOL Share Gains

Alcon U.S. IOL Unit Share




Source: Q1 Market Scope Quarterly Cataract Surgeon Survey

U.S. Aspheric Monofocal Unit Share



Source: Q1 Market Scope Quarterly Cataract Surgeon Survey


Advanced Technology IOL Sales Trend




Source: Company Analysis

Consumer Eye Care Sales

Q2 2008 Sales by Product Line



2nd Qtr



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

(dollars in millions)

Successful Growth in the Optometric Channel

Consumer Products	2007 Market Share	2008 YTD Market Share
OPTI-FREE® EXPRESS®/ RepleniSH® (Branded)	49.0%	51.8%
Systane®	15.0	16.8
ICAPS®	19.7	20.0

Source: Nielsen Consumer Data

Pharmaceutical Products	2007 Market Share	2008 YTD Market Share
Patanol® / Pataday™	78.5%	83.3%
TRAVATAN® and TRAVATAN Z®	33.6	36.4



Source: WK Health

Financial Review

Rick Croarkin

Senior Vice President, Finance and Chief Financial Officer

Q2 Gross Profit





YTD 2007 impacted by refractive impairment

Highlights

- Favorable product sales mix and price increases taken in Q1 2008
- Improvement in manufacturing efficiencies
- Offset by geographic sales mix, foreign exchange and WaveLight integration

Q2 Operating Income





YTD 2007 impacted by refractive impairment

Highlights

- SG&A expenses increased as a percent of sales due to start up costs for Shared Services Center, sales force expansion, and WaveLight
- R&D expense growth slower than growth in sales
- Decrease in amortization expense

Q2 Net Earnings




Highlights


- Strong sales growth, gross profit margin improvement
- Slower growth in operating expenses
- Decline in investment income
- Decrease in effective tax rate due to Swiss tax holiday and period items

Q2 Diluted EPS

Q2
+27.0%




YTD
+26.0%



Cash Flows Analysis

Cash Flows from Operations



2008 Highlights

- Net earnings improvement
- Focus to translate earnings growth to cash flow increase
- 2007 included reduction from investment in trading securities

* Non-GAAP measure

2008 Full Year Financial Guidance Revision

- **Sales range of \$6,460 to \$6,510 million**
- **Diluted earnings per share range of \$6.48 to \$6.54**
- **Includes costs to establish Swiss Shared Service and Marketing Centers and to integrate refractive operations**



Non-GAAP Constant Currency Reconciliation

(dollars in millions)	Q2 GAAP Growth Rate	Exchange Rate Changes	Q2 Constant Currency Growth Rate
Global Sales	17.9%	(6.7)	11.2%
Pharmaceutical	17.6%	(5.5)	12.1%
Surgical	21.6	(8.5)	13.1
Consumer	7.8	(5.6)	2.2
United States	7.0%	--	7.0%
Developed International	28.5	(14.8)	13.7
Emerging Markets	29.5	(10.6)	18.9
(dollars in millions)	YTD GAAP Growth Rate	Exchange Rate Changes	YTD Constant Currency Growth Rate
Global Sales	17.1%	(6.8)	10.3%

Note: Percent Change in Constant Currency calculates sales growth without the impact of foreign exchange fluctuations. Management believes constant currency sales growth is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission. Certain reclassifications have been made to prior year amounts to conform with current year presentation.